Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Pharma USA Inc.

Division of Aurobindo Pharma Ltd.
www.aurobindousa.com

Latest From Aurobindo Pharma USA Inc.

OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies

Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.

OTC Drugs FDA

Aurobindo Integrates Apotex And Prepares For Sandoz

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Sales & Earnings Strategy

Aurobindo Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Commercial Sales & Earnings

Zero Count Adds Up To 70,000-Bottle Ranitidine Recall For AuroMedics

Additional recent recalls include 19,000 bottles of product marketed by Fitoterapia USA and labeled as liquid vitamin C but found to contain erectile dysfunction drug taldalafil .Ongoing testing of ranitidine drugs by FDA and manufacturers led to Aurobindo Pharma USA recall of one lot of OTC 150-mg tablets.

Consumer FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aurobindo Pharma Ltd.
  • Senior Management
  • Swami Iyer, CFO
  • Contact Info
  • Aurobindo Pharma USA Inc.
    Phone: (866) 850-2876
    279 Princeton Hightstown Rd.
    East Windsor, NJ 08520
    USA
UsernamePublicRestriction

Register